Bio-Link Australia

08/08/2024

26/02/2020

This week marks 15 years since the founding of Bio-Link! Thank you to our current and past staff, interns and alumni, clients, colleagues and friends for helping build our business and achieve our goals; to contribute to the discovery, development and commercialisation of biomedical innovations for patients, and to build a strong and sustainable Australian and global biopharma industry.

19/02/2020

“The State of the Biopharmaceutical Industry – 2020”, an annual outlook report published by , ranked Australia third in countries with the most clinical trials planned for 2020. Out of an anticipated 2173 planned clinical trials for this year, Australia takes out just under 100 of them.

The US and China ranked first and second respectively, with 20 per cent of trials planned in the US, while China was a “distant second”.

Most of the clinical trials starting in 2020 will be in phase 2 and the largest therapeutic area for trials will be oncology, with almost 450 trials planned.

;

03/02/2020

What a week and a whole lot of shoe leather! Bio-Link was delighted to represent our client, Actinogen Medical, at . Bio-Link’s Christian Toulli and Actinogen CEO Bill Ketelbey travelled over 31 km (generally on foot) around San Francisco, meeting with leading pharma executives, sharing the latest exciting data and future strategy for the development of for Alzheimer’s disease and other neurological diseases associated with cognitive impairment.

15/01/2020

“Bridging the gap between science & business.”

Don’t miss out on the inaugural Business of Regenerative Medicine Asia Pacific Symposium co-hosted by Bio-Link partner CCRM Australia and the New South Wales Stem Cell Network. The Symposium is a great opportunity to join the field’s leading organisations, industry players and business talent, and discover how to accelerate of .

Register NOW to secure your spot! (Limited tickets available)

Register: https://bit.ly/2NbAG9K

30/10/2019

Are you interested in global business development for your company? Join us at AusBiotech’s annual conference, , and meet Bio-Link's Lilly Bojarski, Senior Business Development Associate. We can help you with all aspects of business development, including commercialisation, deal negotiation and project management.

Learn more: https://bit.ly/2BSAki2

23/10/2019

We are delighted to welcome Kate Samardzic to the Bio-Link team as a Business Development Associate.

Learn more about Kate and the rest of the Bio-Link team: http://bio-link.com/team/

22/10/2019

Check out Bio-Link Australia Executive Director Christian Toouli’s article “The Sacred Word: De-risking biotech messaging” in the new edition of the Australasian Biotechnology journal: https://bit.ly/31tdOa9



About Australasian Biotechnology:

Australasian Biotechnology is AusBiotech’s official journal, bringing us the latest news in biotechnology research and business. AusBiotech is Australia’s Biotechnology Industry Organisation, a not-for-profit limited guarantee company representing over 3000 members in the life sciences arena, dedicated to the development, growth and prosperity of the Australian Biotechnology Industry.

09/10/2019

patients may now receive earlier access to products with the U.S. Food and Drug Administration’s new initiative, . This new development is a collaboration among international regulators to review cancer products concurrently in different countries, eliminating significant regulatory submission delays a product would usually otherwise have.

Patients suffering from advanced endometrial carcinoma now have access to Lenvima (lenvatinib) and Keytruda (pembrolizumab), thanks to the first action of Project Orbis, undertaken by the FDA, Australian Therapeutic Goods Administration - TGA and Health Canada.

Find out more about Project Orbis: https://bit.ly/2kmwl8x

06/10/2019

Congratulations to Actinogen Medical for their breakthrough results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial! Their results show a “significant improvement in cognition in trial participants dosed with Xanamem 20mg daily for 12 weeks, compared to placebo.”

“These are the results we have been looking for. They are hugely important for the development of Xanamem and for the potential for Xanamem to treat Alzheimer’s disease and other conditions associated with cognitive impairment” - Actinogen CEO Dr Bill Ketelbey

25/09/2019

Bio-Link is excited to announce our new partnership with CCRM Australia. They are a not for profit organisation established by Australia’s leading regenerative medicine researchers and companies to accelerate the translation and commercialisation of regenerative medicine discoveries.

22/09/2019

Lasker Foundation has announced the winners of their 2019 . These great researchers join an elite list of recipients that are truly amazing! You may recognise many of those names, including Herbert Boyer, Tom Cech, Kohler and Milstein, Francis Crick, Jonas Salk and many other of the world's most accomplished researchers. Many of them wrote the textbooks you studied, some of them may have even been your supervisors or theirs. Talk about making a mark!

Max D. Cooper and Jaques Miller (top right down) won the 2019 Albert Lasker Basic Medical Research Award for B and T cells – the organising principle of the adaptive immune system.

Dennis J. Slamon, Axel Ullrish and H. Michael Shepard (bottom left to right) won the 2019 Lasker - DeBakey Clinical Medical Research Award for Herceptin – a targeted antibody therapy for breast cancer.

Gavi, the Vaccine Alliance (bottom right corner) won the 2019 Lasker – Bloomberg Public Service Award for Providing sustained access to childhood vaccines around the globe.

Find out more: Laskerfoundation.org/awards/